A carregar...
Population exposure–safety analysis of cediranib for Phase I and II studies in patients with cancer
AIMS: A multistudy analysis of cediranib, a potent, selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR‐1, ‐2 and ‐3), was conducted to establish population exposure–safety models for the relationship of cediranib exposure to the safety endpoints, diastolic and systo...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5867133/ https://ncbi.nlm.nih.gov/pubmed/29274100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13495 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|